Home » Onconova extends agreement with BioClinica
Onconova extends agreement with BioClinica
November 30, 2011
BioClinica has reported that Onconova Therapeutics has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide. Onconova has a number of clinical-stage products and a growing number of pre-clinical candidates. These development stage compounds are novel small molecules for the treatment of a broad range of hematologic malignancies and solid tumors.
“We collaborate with a number of clinical research organizations,” said Dennis C. Earle, vice president of clinical operations at Onconova, “so using BioClinica Express for our trials has helped us to standardize processes. BioClinica has been flexible and responsive, implementing a collaborative, real-time UAT (user acceptance testing) process to help Onconova meet study launch timelines. BioClinica’s forms and study design team, in conjunction with the data management team, have worked together to ensure optimal use of the technology while re-using established eCRFs (electronic case report forms) in order to support rapid study builds.”
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here